Toll-like receptors as a therapeutic target in cancer, infections and inflammatory diseases

被引：23
作者：
Florez-Alvarez, Lizdany [1 ,2 ]
Ruiz-Perez, Lanie [3 ]
Taborda, Natalia [2 ,4 ]
Hernandez, Juan C. [1 ]
机构：
[1] Univ Cooperat Colombia, Fac Med, Infettare, Medellin, Colombia
[2] Univ Antioquia, Fac Med, Grp Inmunovirol, Calle 70 52-21, Medellin, Colombia
[3] Curtin Univ, Sch Pharm & Biomed Sci, Curtin Hlth Innovat Res Inst, GPO Box U1987, Perth, WA 6845, Australia
[4] Corp Univ Remington, Fac Ciencias Salud, Programa Med, Grp Invest Biomed Uniremington, Medellin, Colombia
来源：
IMMUNOTHERAPY | 2020年 / 12卷 / 05期
关键词：
cancer; immune modulators; infectious diseases; inflammation; Toll-like receptors; vaccines; PHASE-I; ULCERATIVE-COLITIS; CLINICAL-OUTCOMES; IMMUNE-RESPONSE; BREAST-CANCER; TLR9; AGONIST; POLYMORPHISMS; SUSCEPTIBILITY; INNATE; ASSOCIATION;
D O I：
10.2217/imt-2019-0096
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Toll-like receptors (TLRs) are widely expressed pattern recognition receptors that bind to conserved molecular patterns expressed by pathogens and damaged cells. After recognition, activated TLRs induce the expression of various proinflammatory and antiviral molecules. Thus, TLRs are potential targets for treatment strategies aimed at boosting the adaptive immune response to vaccines, controlling infections, enhancing immune responses during tumor treatment and attenuating immune responses in inflammatory disorders. This Special Report examines the potential of TLRs as targets for the treatment of cancer, infections and inflammatory diseases. Here, we make a particular emphasis on molecules capable of modulating TLRs and their therapeutic applications.
引用
收藏
页码：311 / 322
页数：12
相关论文
共 111 条
[1]   Toll-like receptors on the fork roads between innate and adaptive immunity [J].
Abdelsadik, Ahmed ;
Trad, Ahmad .
HUMAN IMMUNOLOGY, 2011, 72 (12) :1188-1193
[2]  
Admyre C, 2017, GASTROENTEROLOGY, V152, pS766, DOI 10.1016/S0016-5085(17)32660-4
[3]   A Nonsense Polymorphism (R392X) in TLR5 Protects from Obesity but Predisposes to Diabetes [J].
Al-Daghri, Nasser M. ;
Clerici, Mario ;
Al-Attas, Omar ;
Forni, Diego ;
Alokail, Majed S. ;
Alkharfy, Khalid M. ;
Sabico, Shaun ;
Mohammed, Abdul Khader ;
Cagliani, Rachele ;
Sironi, Manuela .
JOURNAL OF IMMUNOLOGY, 2013, 190 (07) :3716-3720
[4]   M2000 (β-D-Mannuronic Acid) as a Novel Antagonist for Blocking the TLR2 and TLR4 Downstream Signalling Pathway [J].
Aletaha, S. ;
Haddad, L. ;
Roozbehkia, M. ;
Bigdeli, R. ;
Asgary, V. ;
Mahmoudi, M. ;
Mirshafiey, A. .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2017, 85 (02) :122-129
[5]   Clinical efficacy of the Toll-like receptor 9 agonist cobitolimod using patient-reported-outcomes defined clinical endpoints in patients with ulcerative colitis [J].
Atreya, Raja ;
Reinisch, Walter ;
Peyrin-Biroulet, Laurent ;
Scaldaferri, Franco ;
Admyre, Charlotte ;
Knittel, Thomas ;
Kowalski, Jan ;
Neurath, Markus Friedrich ;
Hawkey, Christopher .
DIGESTIVE AND LIVER DISEASE, 2018, 50 (10) :1019-1029
[6]  
Bam RA, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.01369-16, 10.1128/aac.01369-16]
[7]  
Barrett EG, 2013, J INFLAMM LOND S1, V10, P14
[8]   Toll-like receptor 4 D299G polymorphism in metabolic disorders: a meta-analysis [J].
Belforte, F. S. ;
Coluccio Leskow, F. ;
Poskus, E. ;
Penas Steinhardt, A. .
MOLECULAR BIOLOGY REPORTS, 2013, 40 (04) :3015-3020
[9]   Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV [J].
Bergmann, J. F. ;
de Bruijne, J. ;
Hotho, D. M. ;
de Knegt, R. J. ;
Boonstra, A. ;
Weegink, C. J. ;
van Vliet, A. A. ;
van de Wetering, J. ;
Fletcher, S. P. ;
Bauman, L. A. ;
Rahimy, M. ;
Appleman, J. R. ;
Freddo, J. L. ;
Janssen, H. L. A. ;
Reesink, H. W. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 34 (04) :443-453
[10]   Toll-dependent selection of microbial antigens for presentation by dendritic cells [J].
Blander, JM ;
Medzhitov, R .
NATURE, 2006, 440 (7085) :808-812
12345678910